Experts at HLTH Europe 2026 unanimously agreed that rapid acceleration of innovation will not reveal its true benefits until healthcare services can implement new technologies.
The boards of both companies unanimously approved the agreement, which remains subject to shareholder and regulatory approvals.
The recommendation in Europe follows a similar move by the FDA earlier this year.
The newly formed biotech will use the funds to take its eczema bispecific, TALA-125, through to Phase IIb proof-of-concept trials.
The patent expands Anixa’s IP portfolio beyond the US and existing international markets.
The FDA did not identify concerns about the clinical efficacy or safety of NASP that would affect its potential for approval.
